High incidence of Androgenetic Alopecia among patients hospitalized due to severe COVID-19
Observational study on the high incidence of Androgenetic Alopecia among patients hospitalized due to severe COVID-19
Over the past several years there has been increasing reports of JAK inhibitors being used to treat recalcitrant alopecia areata with excellent results in the majority of patients. Currently it is being explored as a potential topical treatment option for treating alopecia areata as well. Overall patients and JAK inhibitors do well with minimal to no side effects but there are portentially serious medical side effects that can occur. Currently, it is not covered by insurance nor FDA approved for alopecia areata. Hopefully, in the near future with more positive data, it will be approved and be an important new treatment option for patients with this devastating hair loss condition.
You Might Also Enjoy...
Observational study on the high incidence of Androgenetic Alopecia among patients hospitalized due to severe COVID-19
The attached study published in the Lancet regarding long-term clinical effects of recovered COVID-19 patients confirms what we have seen in our office over the past several months- increased rates in hair loss.
There appears to be a rare side effect of the new Moderna vaccine. It appears that there is a reaction between a filler and the vaccine induced immune response. The future will determine the precise incidence.
There has been a vastly increased number of people who had COVID in the spring that are now presenting with substantial hair loss.
Due to COVID-19 we are offering telemedicine appointments so that you can communicate with your doctor from the safety of your home.
Laser treatment has been used for hair loss treatment widely since 2008.